Lifeloc Technologies, Inc.: Lifeloc Reports Second Quarter 2026 Results
Lifeloc Technologies (OTC:LCTC) reported Q2 2026 results for the quarter ended June 30. Net revenue rose to $2.445M from $2.219M in Q2 2025, while net loss narrowed to $134k ($0.05/share). Gross margin increased to 45%. The company also said it closed $500k financing at 10.5% interest and is targeting limited SpinDetect drug analyzer launch in Q1 2027.
How this was made
The 30-second read
Why it matters
Traders may reprice the probability-weighted path to SpinDetect beta and limited commercial launch in Q1 2027, while also monitoring cash burn and the secured loan’s implications for balance-sheet risk.
Market read
The release provides fresh quarterly financial datapoints plus a concrete product development timeline (beta now, limited launch Q1 2027) and a secured financing update.
What to watch
The financing is secured by all assets at 10.5% with prime-rate adjustability, which can constrain flexibility if cash needs rise before the SpinDetect launch.
Background
Lifeloc is an OTC-listed developer/manufacturer of breath alcohol and drug testing devices, reporting Q2 2026 results and detailing progress on its SpinDetect oral-fluid analyzer.
Ticker impact
Lifeloc reported Q2 2026 results, including $2.445M revenue, a $134K net loss, and a 10% YoY revenue increase.
Near-term trading likely hinges on whether investors focus on revenue growth and 45% gross margin versus continued net losses and financing terms.
The article provides concrete quarterly revenue, net loss, and margin figures plus a financing update, but it does not include guidance or a clear catalyst beyond the planned SpinDetect beta and Q1 2027 launch.
Market effects
Breath alcohol and drug-testing device makers may see incremental sentiment from progress on an oral-fluid drug analyzer platform, but this is company-specific and not a sector-wide datapoint.
No clear regional macro linkage; operations and customers are described broadly across U.S. and international.
Limited global market relevance given OTC listing and company-specific product development timeline.
Counterpoint
Revenue growth and margin gains may be insufficient if continued R&D burn persists and the SpinDetect commercialization timeline slips beyond Q1 2027.
Key entities
- companyLifeloc Technologies, Inc.
Subject of the earnings release, reporting Q2 2026 financials and SpinDetect development milestones.
- product_platformSpinDetect Centrifugal Drug Analyzer
Oral-fluid drug analyzer platform with disk-based chemistry; beta testing targeted and limited commercial launch planned for Q1 2027.
- financingChairman/CFO secured loan
$500,000 loan closed during the quarter, secured by all assets, at 10.5% interest with prime-rate adjustability.

